Figure 3.

Advantages and disadvantages of CAR T-cell therapy in comparison to TCR therapy. CAR T-cells possess certain advantages over TCR therapy, such as independence from HLA and DCs/APCs. Still, the TCR-based approach has an important benefit based on countless various antigen peptides presented by HLA, thus resulting in a multitude of potential targets. Abbreviations: CAR-T—T-cells with CAR, T—T-cells with TCR, M—macrophage, MDSC—myeloid derived-suppressor cell, Treg—regulatory T-cell, CAF—cancer-associated fibroblasts, PD-L1—programmed death-ligand 1, HLA—human leukocyte antigen; DCs—dendritic cells; APC—antigen-presenting cell.